Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic healthcare solutions serving to enhance the health and well being of people around the globe with well known and respected products that provide healthcare professionals with accurate and cost-effective diagnostic information at the point of care (POC).
Our core competencies and capabilities include:
- Immunoassay development and automated manufacturing
- Lateral Flow (LF): infectious disease, women's health
- Direct Fluorescent Antibodies (DFA) : infectious disease, virology
- Microtiter: bone and complement pathway markers
- Monoclonal antibody characterization and development
- Molecular assay development
We sell our products to professionals for use in physician's offices, hospitals, clinical and reference laboratories, wellness screening centers, and retail clinics.
Quidel commenced operations in 1979 and we launched our first products, dipstick-based pregnancy tests, in 1984. Our product base and technology platforms have expanded through internal development and acquisitions of other products and technologies. The current product areas are infectious diseases, pregnancy, herpes, Graves' Disease, autoimmune diseases and osteoporosis, for professional and research use. During the early 1990's, Quidel successfully embarked on a mission to build its own branded business and market franchises in the professional use markets. As a result, sales are primarily driven by our branded business under the QuickVue® brand name, and the Company enjoys excellent product recognition in its target markets.
In early 2010, the Company acquired Diagnostic Hybrids (DHI) as part of a continued focus on increasing its research and development efforts to accelerate the rate of new product introductions.
The strength of Quidel's brand equity is reflected in the success of QuickVue® in markets around the world. We are extending the QuickVue® brand in select Asian and European markets. We sell through sales representatives for Europe, Middle East, Africa, Asia-Pacific, Latin America and, other international locations, by channeling products through distributor organizations and sales agents. We market our products in the U.S. through a network of national and regional distributors, supported by a direct sales force, and were pleased to be recognized by three of the largest U.S. medical supply distributors as "Supplier of the Year" within the last year.
No reviews to display
Quidel Receives FDA Clearance for its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Bordetella Pertussis
23 Dec 2014
08 May 2014
Quidel Receives Two FDA Clearances for Molecular Diagnostic Tests for Use on Life Technologies QuantStudio™ Dx
16 Sep 2013
Quidel Receives CE Mark for Its Molecular Diagnostic Test for Herpes Simplex Viruses (HSV 1, HSV 2) and Varicella-Zoster Virus (VZV)
29 Mar 2013
FDA Clearance Given to Quidel’s Molecular Diagnostic Test for Respiratory Syncytial Virus and Human Metapneumovirus
14 Mar 2013